Business Context and Reporting Period
Mustang Bio, Inc. filed this Form 8-K on November 30, 2016, reporting the completion of the third closing of a private placement transaction previously announced on October 6, 2016. The company is a Delaware corporation headquartered in New York.
Key Financial Metrics
This filing details a capital raise event rather than periodic operating results. Key financial figures include:
- Gross Proceeds: $12,351,397.50 raised in the third closing.
- Securities Issued: 190.02 Units sold to accredited investors.
- Common Stock Issued: 1,900,215 shares.
- Warrants Issued: Warrants to purchase 475,053 shares of Common Stock.
- Placement Agent Fees: $1,235,139.75 in cash plus a warrant to purchase 190,021 shares.
- Unit Economics: Each Unit sold for $65,000, consisting of 10,000 shares and warrants for 2,500 shares at an exercise price of $8.50.
The filing does not provide data on revenue, profit, operating cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the increase in equity capital and outstanding share count resulting from the third closing. Additionally, on December 6, 2016, the company amended its Placement Agent Agreement to extend the period for subsequent closings of the transaction to January 31, 2017. No other material terms of the agreement were changed.
Outlook, Risks, and Contingencies
The transaction was conducted as a private placement under Section 4(a)(2) and Rule 506 of Regulation D. The filing notes that shares issued in connection with the transaction may not be offered or sold in the United States absent registration or an applicable exemption. The company indicated that subsequent closings may occur through the extended deadline of January 31, 2017.
Investor Verification Checklist
- Verify the total aggregate proceeds raised across all closings of the private placement to date.
- Confirm the total number of shares and warrants outstanding post-closing.
- Review the full text of the Placement Agent Agreement and Amendment for any undisclosed conditions.
- Check the company's Form 10-Q (filed November 14, 2016) and upcoming Form 10-K for the full terms of the Transaction Documents.
- Monitor for any additional closings prior to the January 31, 2017 deadline.